Journal article

Lamivudine and Famciclovir resistant hepatitis B virus associated with fatal hepatic failure

A Ayres, A Bartholomeusz, G Lau, K Lam, J Lee, S Locarnini

Journal of Clinical Virology | Elsevier | Published : 2003


Background: Lamivudine (LMV) is the only nucleoside analogue approved for the treatment of chronic hepatitis B (CHB). LMV, as with other nucleoside analogues including Famciclovir (FCV), suppresses the replication of hepatitis B virus (HBV) by targeting the viral polymerase. However, prolonged antiviral therapy results in the emergence of drug resistance HBV which can contribute to virological breakthroughs and recurrent hepatitis flares. Objectives: A 38-year-old hepatitis B e antigen (HBeAg) positive Chinese female infected with genotype B HBV commenced treatment with FCV and LMV combination therapy but was later maintained on LMV monotherapy. The patient remained HBeAg positive throughout..

View full abstract